Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

August 6, 2020
Open Access

Epigenetic Silencing of LMX1A Contributes to Cancer Progression in Lung Cancer Cells

International Journal of Molecular Sciences
Ti-Hui WuYa-Wen Lin
August 5, 2020

H2AX Promoter Demethylation at Specific Sites Plays a Role in STAT5-Induced Tumorigenesis

Journal of Mammary Gland Biology and Neoplasia
Sharon Havusha-LauferItamar Barash
July 28, 2020
Open Access

NKX6.1 Represses Tumorigenesis, Metastasis, and Chemoresistance in Colorectal Cancer

International Journal of Molecular Sciences
Hsin-Hua ChungYu-Lueng Shih
August 1, 2020
Open Access

LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma

Cancers
Alberto M ArenasPedro P Medina
August 6, 2020
Review
Open Access

The Protective Effect of Polyphenols for Colorectal Cancer

Frontiers in Immunology
Sujuan DingHongmei Jiang
August 5, 2020
Open Access

Quercetin-Resveratrol Combination for Prostate Cancer Management in TRAMP Mice

Cancers
Chandra K SinghNihal Ahmad
July 31, 2020
Review
Open Access

Targeting Epigenetic Modifications in Uveal Melanoma

International Journal of Molecular Sciences
Pooneh Chokhachi BaradaranBozena Smolkova
July 31, 2020
Open Access

Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

BMC Cancer
Andy GöbelTilman D Rachner
August 5, 2020
Review
Open Access

The role of histone methylation in the development of digestive cancers: a potential direction for cancer management

Signal Transduction and Targeted Therapy
Yuan ChenYupei Zhao
July 28, 2020
Open Access

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

Blood Advances
Thomas E C CumminMatthew J Carter
July 24, 2020
Open Access

Transition to naïve human pluripotency mirrors pan-cancer DNA hypermethylation

Nature Communications
Hemalvi PataniGabriella Ficz
July 28, 2020
Review
Open Access

Type III intermediate filaments as targets and effectors of electrophiles and oxidants

Redox Biology
Álvaro Viedma-PoyatosDolores Pérez-Sala
July 30, 2020
Open Access

Tumor DNA hypomethylation of LINE-1 is associated with low tumor grade of breast cancer in Tunisian patients

Oncology Letters
Hayet Radia ZeggarMaher Kharrat

Sign up to follow this feed and discover related papers.

Related Feeds

Aging Genetics (Keystone)

This feed focuses on aging epidemiology and genetic, epigenetic, and proteomic aspects underlying aging, as well as aging- associated biomarkers. Here the latest research in this domain.

Anthracycline Sensitivity & Chromatin (Keystone)

Anthracyclines are used in the treatment of cancer and work by inhibiting topoisomerase II (TOP2). Recent evidence suggests that because DNA accessibility is crucial for TOP2 binding, chromatin regulatory genes should predict anthracycline response. Find the latest research on anthracycline sensitivity and chromatin regulators in this feed.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chemical Tools (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Using novel chemical tools allows us to learn more about these epigenetic changes and how they impact the neoplastic process. Follow this feed to learn more about cancer epigenetics and chemical tools.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

© 2020 Meta ULC. All rights reserved
/feed-previews/cancer-epigenetics-metabolism/0ca6bbe9-355f-4ca7-95a4-d30cc28ecdf2